STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

STJ

1,199

+1.05%↑

HIK

1,404.5

+1.08%↑

HILS

2,490

-3.11%↓

Kodu・Aktsiate loetelu・GlaxoSmithKline PLC

GlaxoSmithKline PLC

Suletud

SektorTervishoid

1,846.25 0.29

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1841

Max

1869.25

Põhinäitajad
By Trading Economics
Sissetulek	1.2B 1.8B
Müük	-989M 7.6B
P/E Sektori keskmine	13.387 49.8
Aktsiakasum	0.465
Dividenditootlus	3.47
Kasumimarginaal	24.105
Töötajad	66,841
EBITDA	577M 2.8B

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+7.24% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	3.47% 2.25%
Järgmine tulemuste avaldamine	29. juuli 2026
Järgmine dividendimakse kuupäev	9. juuli 2026
Järgmine aktsia dividendi kuupäev (ex-date)	14. mai 2026

Turustatistika
By TradingEconomics
Turukapital	-4.2B 76B
Eelmine avamishind	1845.96
Eelmine sulgemishind	1846.25

Uudiste sentiment

By Acuity

56%

44%

271 / 347 Pingereas Healthcare

GlaxoSmithKline PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. apr 2026, 06:42 UTC

Tulu

GSK Earnings Boosted by Higher Specialty Medicine Sales

6. mai 2026, 13:35 UTC

Market Talk

GSK Is Taking Steps in Right Direction, But Might Need More -- Market Talk

29. apr 2026, 10:39 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

GSK CEO Sees RAPT Therapeutics Acquisition as Template for Future Deals -- Market Talk

29. apr 2026, 10:06 UTC

Market Talk

Tulu

AstraZeneca, GSK Results Fail to Impress Market -- Market Talk

29. apr 2026, 10:02 UTC

Market Talk

Tulu

GSK Makes Ideal Start for New CEO -- Market Talk

29. apr 2026, 06:07 UTC

Tulu

GSK PLC Sees 70p 2026 Dividend Payout

29. apr 2026, 06:07 UTC

Tulu

GSK PLC Declares Dividend of 17p

29. apr 2026, 06:07 UTC

Tulu

GSK PLC Free Cash Flow of GBP0.8B

29. apr 2026, 06:06 UTC

Tulu

GSK PLC Cash Generated From Operations GBP1.4B

29. apr 2026, 06:06 UTC

Tulu

GSK PLC 1Q General Medicines Sales GBP2.3B

29. apr 2026, 06:06 UTC

Tulu

GSK PLC 1Q Vaccines Sales GBP2.1B

29. apr 2026, 06:06 UTC

Tulu

GSK PLC 1Q Specialty Medicines Sales GBP3.2B

29. apr 2026, 06:05 UTC

Tulu

Analysts Saw GSK PLC 1Q Net Profit at GBP1.74B

29. apr 2026, 06:04 UTC

Tulu

Analysts Saw GSK 1Q Adjusted Operating Profit of GBP2.46B

29. apr 2026, 06:04 UTC

Tulu

GSK PLC 1Q Adjusted Operating Profit GBP2.65B

29. apr 2026, 06:04 UTC

Tulu

Analysts Saw GSK PLC Core EPS of 43.3p

29. apr 2026, 06:04 UTC

Tulu

Analysts Saw GSK PLC 1Q Turnover at GBP7.58B

29. apr 2026, 06:04 UTC

Tulu

GSK PLC 1Q Adj EPS 46.50p

29. apr 2026, 06:01 UTC

Tulu

GSK PLC Sees 2026 Adjusted EPS Growth of 7%-9%

29. apr 2026, 06:01 UTC

Tulu

GSK PLC Sees 2026 Adjusted Oper Pft Growth of 7%-9%

29. apr 2026, 06:01 UTC

Tulu

GSK PLC Sees 2026 Turnover Growth of 3%-5%

29. apr 2026, 06:01 UTC

Tulu

GSK PLC Backs 2026 View

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q EPS 42.6p

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q Turnover GBP7.63B

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q Pretax Pft GBP2.14B

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q Oper Pft GBP2.29B

29. apr 2026, 06:00 UTC

Tulu

GSK PLC 1Q Net Pft GBP1.74B

15. apr 2026, 06:12 UTC

Omandamised, ülevõtmised, äriostud

GSK Completes Acquisition of 35Pharma

10. apr 2026, 10:43 UTC

Market Talk

GSK Could Report Weak General Medicines Results -- Market Talk

31. märts 2026, 14:02 UTC

Omandamised, ülevõtmised, äriostud

Samsung Biologics Will Continue Supplying Products Previously Manufactured at Site to GSK Under Terms of Agreement

Võrdlus sarnastega

Hinnamuutus

GlaxoSmithKline PLC Prognoos

Hinnasiht

By TipRanks

7.24% tõus

12 kuu keskmine prognoos

Keskmine 1,976.36 GBX 7.24%

Kõrge 2,630 GBX

Madal 1,500 GBX

Põhineb 13 Wall Streeti analüütiku instrumendi GlaxoSmithKline PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

13 ratings

Osta

Hoia

Müü

Põhineb 13 analüütiku instrumendi GlaxoSmithKline PLC aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

271 / 347 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest GlaxoSmithKline PLC

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.